Major flu strain resistant to widely used antiviral drug

January 15, 2009 By Kyung M. Song

One of the major strains of the influenza virus this season has become resistant to Tamiflu - rendering the mainstay antiviral drug all but impotent and creating tough treatment options for patients who come down with the flu.

On Dec. 19, the federal Centers for Disease Control and Prevention (CDC) alerted local health authorities that an early testing of the most common type of seasonal flu found that it has become virtually impervious to Tamiflu.

The resistance, apparently triggered by a spontaneous mutation in the virus, comes three years after a different subtype of the flu virus became widely resistant to another drug class.

In response, state and local health officials are advising doctors to hedge their treatments by simultaneously prescribing Tamiflu and a second antiviral medicine. The hope is that the combination will work against influenza A virus before doctors have a chance to identify the particular strain.

But doubling up on the medicine not only drives up costs but also could put patients at higher risk for side effects - some potentially serious.

"The decision to treat now is much more difficult," said Dr. Yuan-Po Tu, an associate medical director at The Everett Clinic who oversees its flu shot clinic.

All that underscores the value of getting vaccinated to ward off the flu in the first place, Tu said.

Tu said he was startled at how quickly the virus became resistant to Tamiflu. During the 2007-2008 flu season, 11 percent of the H1N1virus, one of the two subtypes of influenza A, was found to be Tamiflu-resistant. So far this season, a small sampling tested by the CDC found the resistance has grown to 98 percent.

Since January 2006, Tamiflu has been the only antiviral option for millions of Americans - including all children under 7 - after another influenza A strain, H3N2, became resistant to an older class of antivirals called adamantanessold as amantadine or rimantadine. Adamantanes do not work against a third virus strain, influenza B, but Tamiflu does. Another antiviral, Relenza, is effective against all three strains. But Relenza is not widely available and comes in a powder form that is difficult for some patients to inhale.

What's more, lab tests to distinguish between H1N1 and H3N2 strains can take up to a week, too late for flu patients, who must start antiviral therapy within 48 hours of symptoms (testing for influenza A or B can be done in as little as an hour).

That left Tamiflu as the preferred all-purpose drug because - at least until the new resistance - it worked against all three flu strains and was well tolerated by patients. "We could lose a very, very useful drug very, very quickly," Tu said.

Tu said amantadine, on the other hand, can cause such side effects as disorientation, especially if it's taken for longer than five days. And in rare cases, some patients have reported having suicidal thoughts while taking amantadine. But amantadine is much cheaper than Tamiflu, with a retail price of about $18 for five days, compared with $127.

The public-health risks from the Tamiflu resistance will depend on the severity of a flu outbreak and whether H1N1 turns out to be the predominant strain, said Dr. Jeff Duchin, chief of communicable-diseases section of Public Health - Seattle & King County.

Duchin said the Tamiflu resistance won't be a problem for most people who get the flu. But patients in hospitals and nursing homes or others with weakened immune systems face greater danger.

"For a small subset of people, antiviral can be a lifesaver," Duchin said.

The dominant strain can vary from season to season and even from community to community, said Dr. Marcia Goldoft, an epidemiologist with the communicable-diseases section of state Department of Health.

In some years, the flu season is over by the first part of January; other years, it doesn't get going until February, Goldoft said. Normally, flu cases peak in February or March.

Duchin said it's not too late for flu shots, which take about 10 days to build immunity. This year's vaccine is well matched against the current strain. Depending on the years, vaccines can prevent anywhere from 40 percent to 85 percent of people from getting the flu, he said.

"If you are really worried about the flu, vaccination is the best option," Duchin said.

Each year, some 36,000 Americans - the vast majority of them elderly - die of flu. But children, the most efficient transmitters of virus and bacteria, account for the biggest share of flu cases.

Federal guidelines recommend annual flu shots for everyone between 6 months and 18, and 50 and older, as well as pregnant women and people with chronic medical conditions or weakened immune systems. Health care workers and those who care for small children also are encouraged to get vaccinated.

But only 30 percent of American adults had gotten flu shots by mid-November this season, according to a survey by Rand Health, a research arm of the nonprofit think tank Rand Corp.

Among adults for whom vaccination is recommended, the rate was only slightly higher, at 37 percent.


© 2009, The Seattle Times.
Visit The Seattle Times Extra on the World Wide Web at
Distributed by McClatchy-Tribune Information Services.

Explore further: Flu shot only 36 percent effective, making bad year worse (Update)

Related Stories

Flu shot only 36 percent effective, making bad year worse (Update)

February 15, 2018
The flu vaccine is doing a poor job protecting older Americans and others against the bug that's causing most illnesses.

Flu shot won't make you spread more influenza

February 15, 2018
Getting the flu shot won't make you spread the disease more, doesn't weaken your immune system but it does offer some protection from getting infected, despite misleading claims on social media.

IFN-mediated immunity to influenza A virus infection influenced by RIPK3 protein

February 15, 2018
Each year, influenza kills half a million people globally with the elderly and very young most often the victims. In fact, the Centers for Disease Control and Prevention reported 37 children have died in the United States ...

The search for a universal influenza vaccine

February 16, 2018
The current 2017-18 flu season is a bad one. Hospitalization rates are now higher than in recent years at the same point, and infection rates are still rising. The best line of defense is the seasonal influenza vaccine. But ...

It's a century since the 1918 flu pandemic - could it happen again?

February 7, 2018
(HealthDay)—One hundred years ago, the deadliest influenza pandemic of all time made a ravaging march across the globe.

Nanoparticle vaccine offers universal protection against influenza A viruses, study finds

January 24, 2018
Researchers have developed a universal vaccine to combat influenza A viruses that produces long-lasting immunity in mice and protects them against the limitations of seasonal flu vaccines, according to a study led by Georgia ...

Recommended for you

Past encounters with the flu shape vaccine response

February 20, 2018
New research on why the influenza vaccine was only modestly effective in recent years shows that immune history with the flu influences a person's response to the vaccine.

Building better tiny kidneys to test drugs and help people avoid dialysis

February 16, 2018
A free online kidney atlas built by USC researchers empowers stem cell scientists everywhere to generate more human-like tiny kidneys for testing new drugs and creating renal replacement therapies.

Expanding Hepatitis C testing to all adults is cost-effective and improves outcomes

February 16, 2018
According to a new study, screening all adults for hepatitis C (HCV) is a cost-effective way to improve clinical outcomes of HCV and identify more infected people compared to current recommendations. Using a simulation model, ...

Study suggests expanded range for emerging tick-borne disease

February 16, 2018
Human cases of Borrelia miyamotoi, a tick-borne infection with some similarities to Lyme disease, were discovered in the eastern United States less than a decade ago. Now new research led by the Yale School of Public Health ...

A new class of drug to treat herpes simplex virus-1 infection

February 14, 2018
For patients with the herpes simplex-1 virus (HSV-1), there are just a handful of drugs available to treat the painful condition that can affect the eyes, mouth and genitals.

Organ-on-chip technology enters next stage as experts test hepatitis B virus

February 14, 2018
Scientists at Imperial College London have become the first in the world to test how pathogens interact with artificial human organs.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.